GUIDELINES ON THE DIAGNOSIS, INVESTIGATION AND INITIAL The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDELINES | BRITISH SOCIETY FOR HAEMATOLOGYMEMBERSHIPTHE MANAGEMENT OF PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: GOOD PRACTICE PAPER The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDANCE PRODUCED FROM THE EXPERT HAEMATOLOGY PANEL (EHP Media Statement on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination. BSH has informed the UK haematological community about this complication and is working with the Expert Haematology Panel to issue regular updated guidance as to how to best investigate and manage this condition. NEW BLOOD GROUP LINK TO COVID RISK An important gene involved in determining a person’s blood group is closely linked to the risk of disease from COVID-19 infection, according to a new analysis. INVESTIGATION AND MANAGEMENT OF VENOUS THROMBOSIS AT The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. DIAGNOSIS AND MANAGEMENT OF RARE COAGULATION DISORDERS The objective of this document is to guide diagnosis and management of patients with rare coagulation disorders in the UK. The disorders described in this document include heritable deficiencies of fibrinogen, prothrombin, factor (F) V, FVII, FX, FXI and FXIII, combined FV and FVIII deficiency and vitamin K-dependent coagulation

factor deficiency.

GUIDELINE ON THE DIAGNOSIS AND MANAGEMENT OF CHRONIC The management of chronic myeloid leukaemia (CML) has seen considerable change in the last several years. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of CML in adults and children. DIAGNOSIS AND MANAGEMENT OF POLYCYTHAEMIA VERA The previous guideline was published in 2005 (McMullin et al, 2005) with an amendment in 2007 (McMullin et al, 2007) to update the diagnostic criteria following the discovery of the JAK 2 mutation in patients with polycythaemia vera (PV). Since that time, there has been a considerable amount of research in the area concerning diagnostics, risk stratification, new agents and reinvestigation of DIAGNOSIS AND MANAGEMENT OF ACQUIRED COAGULATION FACTOR Acquired coagulation inhibitors result from immune-mediated depletion or inhibition of a coagulation factor. Inhibitors are most commonly directed against factor VIII (FVIII) and von Willebrand factor (VWF) and inhibitors against other coagulation factors are only occasionally

reported.

LABORATORY INVESTIGATION OF HERITABLE DISORDERS OF The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDELINES ON THE DIAGNOSIS, INVESTIGATION AND INITIAL The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDELINES | BRITISH SOCIETY FOR HAEMATOLOGYMEMBERSHIPTHE MANAGEMENT OF PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: GOOD PRACTICE PAPER The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDANCE PRODUCED FROM THE EXPERT HAEMATOLOGY PANEL (EHP Media Statement on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination. BSH has informed the UK haematological community about this complication and is working with the Expert Haematology Panel to issue regular updated guidance as to how to best investigate and manage this condition. NEW BLOOD GROUP LINK TO COVID RISK An important gene involved in determining a person’s blood group is closely linked to the risk of disease from COVID-19 infection, according to a new analysis. INVESTIGATION AND MANAGEMENT OF VENOUS THROMBOSIS AT The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. DIAGNOSIS AND MANAGEMENT OF RARE COAGULATION DISORDERS The objective of this document is to guide diagnosis and management of patients with rare coagulation disorders in the UK. The disorders described in this document include heritable deficiencies of fibrinogen, prothrombin, factor (F) V, FVII, FX, FXI and FXIII, combined FV and FVIII deficiency and vitamin K-dependent coagulation

factor deficiency.

GUIDELINE ON THE DIAGNOSIS AND MANAGEMENT OF CHRONIC The management of chronic myeloid leukaemia (CML) has seen considerable change in the last several years. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of CML in adults and children. DIAGNOSIS AND MANAGEMENT OF POLYCYTHAEMIA VERA The previous guideline was published in 2005 (McMullin et al, 2005) with an amendment in 2007 (McMullin et al, 2007) to update the diagnostic criteria following the discovery of the JAK 2 mutation in patients with polycythaemia vera (PV). Since that time, there has been a considerable amount of research in the area concerning diagnostics, risk stratification, new agents and reinvestigation of DIAGNOSIS AND MANAGEMENT OF ACQUIRED COAGULATION FACTOR Acquired coagulation inhibitors result from immune-mediated depletion or inhibition of a coagulation factor. Inhibitors are most commonly directed against factor VIII (FVIII) and von Willebrand factor (VWF) and inhibitors against other coagulation factors are only occasionally

reported.

LABORATORY INVESTIGATION OF HERITABLE DISORDERS OF The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 02645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. GUIDELINE ON THE DIAGNOSIS AND MANAGEMENT OF CHRONIC The management of chronic myeloid leukaemia (CML) has seen considerable change in the last several years. The objective of this guideline is to provide healthcare professionals with clear guidance on the investigation and management of CML in adults and children. DIAGNOSIS AND MANAGEMENT OF POLYCYTHAEMIA VERA The previous guideline was published in 2005 (McMullin et al, 2005) with an amendment in 2007 (McMullin et al, 2007) to update the diagnostic criteria following the discovery of the JAK 2 mutation in patients with polycythaemia vera (PV). Since that time, there has been a considerable amount of research in the area concerning diagnostics, risk stratification, new agents and reinvestigation of DIAGNOSIS AND MANAGEMENT OF ACQUIRED COAGULATION FACTOR Acquired coagulation inhibitors result from immune-mediated depletion or inhibition of a coagulation factor. Inhibitors are most commonly directed against factor VIII (FVIII) and von Willebrand factor (VWF) and inhibitors against other coagulation factors are only occasionally

reported.

GUIDELINE FOR DIAGNOSIS AND MANAGEMENT OF HAIRY CELL Hairy cell leukaemia (HCL) is an uncommon, chronic B cell leukaemia, first reported as a distinct entity in the 1950s. 1, 2 HCL accounts for 2% of lymphoid leukaemias, with a male predominance and median age at diagnosis of 58 years. Classical HCL and its variant form (HCL‐V) are now regarded as separate entities, 3 with different cytological, haematological and immunophenotypic features. DIAGNOSIS AND MANAGEMENT OF APLASTIC ANAEMIA This is a comprehensive but pragmatic new guideline and focuses on the accurate diagnosis, delineation of severity types and subsequent

management of

GUIDELINES ON THE USE OF IRRADIATED BLOOD COMPONENTS

"

data-main-title="UK Haematology 1960 - 2020" data-main-text=" We invited our members and the broader haematology community to tell us what they believe to be the most significant advances in UK haematology during the lifetime of BSH. The timeline reflects the milestones and moments they believe to be of importance and of which they are most proud. From its inception, the timeline was envisaged as a community-led activity, rather than a scientific study or formal academic research, and there will undoubtedly be gaps.  What have we missed? We welcome further contributions. Please send details of advances from the past 60 years that have not been included to janet@b-s-h.org.uk. The timeline has been collated with the best intentions but please let us know if you spot any errors. Use the filters below to select sub-specialties.

">

This site uses cookies to store information. Press accesskey C to learn more about your options.

Cookie Control Icon

Cookie Control Close Icon

OUR USE OF COOKIES.

We use necessary cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. We won't set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences. For more detailed information about the cookies we use, see our Cookies Page.Cookie Control Link Icon Accept Recommended Settings -------------------------

NECESSARY COOKIES

Enable core functionality such as page navigation and access to secure areas. You can disable these by changing your browser preferences, but the website cannot function properly without these cookies. -------------------------

ANALYTICS

Help us to improve our website by collecting and reporting information

on its usage.

AnalyticsOnOff

-------------------------

Close